NR 566 Midterm Exam (2026) | Chamberlain Advanced
Pharmacology Actual Questions and Answers (PDF)
INTRODUCTION
This comprehensive study guide features verified multiple-choice
questions covering the most frequently tested topics on the NR 566
Advanced Pharmacology Midterm Examination at Chamberlain, including
antifungal agents (amphotericin B, itraconazole, caspofungin,
griseofulvin), antiviral drugs (acyclovir, oseltamivir), antiretroviral
therapy (NRTIs, protease inhibitors, INSTIs, CCR5 antagonists), antibiotics
and antimicrobial stewardship, pharmacokinetics and pharmacodynamics,
drug-drug interactions (CYP450 system), and anthelmintic medications.
Each question includes the correct answer in bold italics with a detailed
clinical rationale explaining the mechanism of action, adverse effects,
drug interactions, and clinical prescribing considerations based on
current guidelines and primary pharmacology references. Based on the
latest 2026/2027 NR 566 exam standards, this resource is designed for
Family Nurse Practitioner (FNP) and graduate nursing students preparing
for the Advanced Pharmacology midterm exam.
,SECTION 1: ANTIFUNGAL AGENTS
Question 1
Which antifungal agent requires a patient to avoid simvastatin due to the
risk of rhabdomyolysis from CYP3A4 inhibition?
A) Fluconazole
B) Itraconazole
C) Terbinafine
D) Amphotericin B
Answer: B) Itraconazole
Explanation: Itraconazole potently inhibits the CYP3A4 enzyme,
significantly increasing plasma concentrations of HMG-CoA reductase
inhibitors like simvastatin, leading to myopathy and rhabdomyolysis.
Prescribers must either switch to pravastatin (which is not metabolized
by CYP3A4) or select an alternative antifungal agent. Fluconazole also
inhibits CYP3A4 but to a lesser extent; terbinafine and amphotericin B do
not have this significant interaction .**
Question 2
Which statement best explains why amphotericin B must be given
intravenously for systemic mycoses?
,A) It is rapidly metabolized by first-pass hepatic metabolism
B) It has very poor GI absorption, so therapeutic serum levels for
systemic mycoses can only be achieved with IV administration
C) It causes severe GI distress when given orally
D) It requires direct injection into the bloodstream to activate
Answer: B) It has very poor GI absorption, so therapeutic serum
levels for systemic mycoses can only be achieved with IV
administration
Explanation: Amphotericin B has very poor GI absorption; therapeutic
serum levels for systemic mycoses can only be achieved with IV
administration. After leaving the vascular space, it binds extensively to
sterol-containing membranes, but oral dosing does not provide adequate
bioavailability for systemic infection. Therefore, oral amphotericin B is
only used for gastrointestinal fungal infections .**
Question 3
What is the standard loading dose for caspofungin when treating invasive
aspergillosis?
A) 50 mg IV
B) 70 mg IV
C) 100 mg IV
D) 150 mg IV
Answer: B) 70 mg IV
, Explanation: The standard loading dose for caspofungin is 70 mg IV on
day 1, followed by 50 mg IV daily thereafter. Caspofungin is an
echinocandin antifungal agent indicated for invasive aspergillosis that is
unresponsive to amphotericin B or itraconazole .**
Question 4
An elderly patient with achlorhydria may have reduced absorption of
standard itraconazole formulations. Why does this occur?
A) Itraconazole requires an acidic environment for dissolution
B) Achlorhydria increases renal clearance
C) Gastric acid destroys itraconazole
D) Achlorhydria induces CYP3A4 enzymes
Answer: A) Itraconazole requires an acidic environment for
dissolution
Explanation: Standard itraconazole capsules require gastric acid for
proper dissolution and absorption. Elderly patients with achlorhydria or
those taking proton pump inhibitors achieve subtherapeutic drug levels
unless switched to the SUBA-itraconazole formulation designed for
absorption at higher pH .**
Question 5
Pharmacology Actual Questions and Answers (PDF)
INTRODUCTION
This comprehensive study guide features verified multiple-choice
questions covering the most frequently tested topics on the NR 566
Advanced Pharmacology Midterm Examination at Chamberlain, including
antifungal agents (amphotericin B, itraconazole, caspofungin,
griseofulvin), antiviral drugs (acyclovir, oseltamivir), antiretroviral
therapy (NRTIs, protease inhibitors, INSTIs, CCR5 antagonists), antibiotics
and antimicrobial stewardship, pharmacokinetics and pharmacodynamics,
drug-drug interactions (CYP450 system), and anthelmintic medications.
Each question includes the correct answer in bold italics with a detailed
clinical rationale explaining the mechanism of action, adverse effects,
drug interactions, and clinical prescribing considerations based on
current guidelines and primary pharmacology references. Based on the
latest 2026/2027 NR 566 exam standards, this resource is designed for
Family Nurse Practitioner (FNP) and graduate nursing students preparing
for the Advanced Pharmacology midterm exam.
,SECTION 1: ANTIFUNGAL AGENTS
Question 1
Which antifungal agent requires a patient to avoid simvastatin due to the
risk of rhabdomyolysis from CYP3A4 inhibition?
A) Fluconazole
B) Itraconazole
C) Terbinafine
D) Amphotericin B
Answer: B) Itraconazole
Explanation: Itraconazole potently inhibits the CYP3A4 enzyme,
significantly increasing plasma concentrations of HMG-CoA reductase
inhibitors like simvastatin, leading to myopathy and rhabdomyolysis.
Prescribers must either switch to pravastatin (which is not metabolized
by CYP3A4) or select an alternative antifungal agent. Fluconazole also
inhibits CYP3A4 but to a lesser extent; terbinafine and amphotericin B do
not have this significant interaction .**
Question 2
Which statement best explains why amphotericin B must be given
intravenously for systemic mycoses?
,A) It is rapidly metabolized by first-pass hepatic metabolism
B) It has very poor GI absorption, so therapeutic serum levels for
systemic mycoses can only be achieved with IV administration
C) It causes severe GI distress when given orally
D) It requires direct injection into the bloodstream to activate
Answer: B) It has very poor GI absorption, so therapeutic serum
levels for systemic mycoses can only be achieved with IV
administration
Explanation: Amphotericin B has very poor GI absorption; therapeutic
serum levels for systemic mycoses can only be achieved with IV
administration. After leaving the vascular space, it binds extensively to
sterol-containing membranes, but oral dosing does not provide adequate
bioavailability for systemic infection. Therefore, oral amphotericin B is
only used for gastrointestinal fungal infections .**
Question 3
What is the standard loading dose for caspofungin when treating invasive
aspergillosis?
A) 50 mg IV
B) 70 mg IV
C) 100 mg IV
D) 150 mg IV
Answer: B) 70 mg IV
, Explanation: The standard loading dose for caspofungin is 70 mg IV on
day 1, followed by 50 mg IV daily thereafter. Caspofungin is an
echinocandin antifungal agent indicated for invasive aspergillosis that is
unresponsive to amphotericin B or itraconazole .**
Question 4
An elderly patient with achlorhydria may have reduced absorption of
standard itraconazole formulations. Why does this occur?
A) Itraconazole requires an acidic environment for dissolution
B) Achlorhydria increases renal clearance
C) Gastric acid destroys itraconazole
D) Achlorhydria induces CYP3A4 enzymes
Answer: A) Itraconazole requires an acidic environment for
dissolution
Explanation: Standard itraconazole capsules require gastric acid for
proper dissolution and absorption. Elderly patients with achlorhydria or
those taking proton pump inhibitors achieve subtherapeutic drug levels
unless switched to the SUBA-itraconazole formulation designed for
absorption at higher pH .**
Question 5
